The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 6, 2000, Pages 626-636

  Schwartz, Jules I ^a,b,c,d,e,f   Bugianesi, Kathleen J ^a,b,c,d,e,f   Ebel, David L ^a,b,c,d,e,f   De Smet, Marina ^a,b,c,d,e,f   Haesen, Rita ^a,b,c,d,e,f   Larson, Patrick J ^a,b,c,d,e,f   Ko, Amy ^a,b,c,d,e,f   Verbesselt, Rene ^a,b,c,d,e,f   Hunt, Thomas L ^a,b,c,d,e,f   Lins, Robert ^a,b,c,d,e,f   Lens, Simone ^a,b,c,d,e,f   Porras, Arturo G ^a,b,c,d,e,f   Dieck, John ^a,b,c,d,e,f   Keymeulen, Bart ^a,b,c,d,e,f   Gertz, Barry J ^a,b,c,d,e,f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Research Laboratories Europe   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d PPD Inc ^*  (Belgium)

^e Pharmaceutical Product Development   (United States)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFECOXIB; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ENANTIOMER; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL STANDARD UNIT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANTICOAGULANTS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LACTONES; MALE; PROTHROMBIN TIME; SULFONES; WARFARIN;

EID: 0034527444     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.112244     Document Type: Article

References (18)

1. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
2. Selective inhibition of the cyclooxygenase-2 isoform: Evaluation of analgesic response in patients following third molar extraction
3. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
4. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
5. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
6. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6-week double-blind, placebo-controlled pilot study of rofecoxib
7. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
8. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than aspirin or ibuprofen
9. COX-2 specific inhibition with MK-0966 25 or 50 mg QD over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg TID
10. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg TID
11. Oral anticoagulant drugs
12. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans
13. Phenylbutazone-warfarin interaction in man: Further stereochemical and metabolic considerations
14. Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma
15. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
16. Anticoagulant, thrombolytic, and antiplatelet drugs
17. Human P450 metabolism of warfarin
18. Hydroxylation of warfarin by human CDNA-expressed cytochrome P-450: A role of P4502C9 in the etiology of (S)-warfarin-drug interactions